King Faisal Specialist Hospital   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Riyadh Saudi Arabia (1975)

Organization Overview

First Clinical Trial
2001
NCT00531583
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

KFSHRC | KFSH & RC | KFSH&RC | KFSH & RC, Riyadh | KFSH&RC, Riyadh | KFSH&RC, Riyadh, Saudi Arabia | King Faisal Specialist Hospital And Research Center | King Faisal Specialist Hospital & Research Center, Riyadh, Kingdom of Saudi Arabia | King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia | King Faisal Specialist Hospital & Research Center (Riydah) | King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia | King Faisal Specialist Hospital & Research Centre, Saudi Arabia | Oncology Center, King Faisal Specialist Hospital & Research Center | Research Center, King Faisal Specialist Hospital & Research Center

Active Ingredients

Drugs in Phase 4 Trials (11)

calcium phosphate (1 trial)

chlorhexidine (hibitane) (1 trial)

ergocalciferol (drisdol) (3 trials)

insulin glargine (toujeo) (1 trial)

insulin human (humulin) (1 trial)

interferon alpha-2b (Intron-A) (2 trials)

nystatin (mycostatin) (1 trial)

ribavirin (virazole) (1 trial)

sodium bicarbonate (1 trial)

sorafenib (nexavar) (1 trial)

vitamin d3 (5 trials)

Drugs in Phase 3 Trials (9)

cisplatin (platinol) (4 trials)

cyclophosphamide (cytoxan) (4 trials)

docetaxel (taxotere) (4 trials)

gemcitabine (gemzar) (2 trials)

goserelin (zoladex) (1 trial)

methotrexate (1 trial)

oxygen (1 trial)

ozone (1 trial)

temozolomide (temodar) (1 trial)

Drugs in Phase 2 Trials (10)

Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (1 trial)

bevacizumab (avastin) (2 trials)

capecitabine (xeloda) (1 trial)

COVID-19 convalescent plasma (1 trial)

durvalumab (imfinzi) (1 trial)

everolimus (zortress) (1 trial)

fluorouracil (efudex) (2 trials)

irinotecan (Camptosar) (1 trial)

paclitaxel (taxol) (4 trials)

sunitinib (sutent) (2 trials)

Drugs in Phase 1 Trials (2)

adeno-associated virus (1 trial)

mycophenolate (CellCept) (1 trial)

Drugs in Other Trials (16)

bacille calmette-guerin (1 trial)

caffeine (1 trial)

carboplatin (paraplatin) (2 trials)

dactinomycin (cosmegen) (1 trial)

doxorubicin (Doxil) (3 trials)

doxycycline (vibramycin) (1 trial)

epirubicin (ellence) (1 trial)

esomeprazole (nexium) (1 trial)

glycerin (1 trial)

ifosfamide (ifex) (1 trial)

imatinib (gleevec) (1 trial)

levofloxacin (levaquin) (1 trial)

peripheral blood lymphocytes (1 trial)

tamoxifen (nolvadex) (1 trial)

trastuzumab (herceptin) (1 trial)

vincristine (oncovin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Disease (Phase 3)

Adenocarcinoma (Phase 2)

Anemia (Phase 2)

Anemia, Aplastic (Phase 2)

Breast Neoplasms (Phase 3)

Carcinoma (Phase 4)

Carcinoma, Hepatocellular (Phase 4)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Renal Cell (Phase 2)

Coronary Artery Disease (Phase 3)

Diabetes Mellitus, Type 2 (Phase 3)

Esophageal Neoplasms (Phase 2)

Gastrointestinal Neoplasms (Phase 4)

Glioblastoma (Phase 3)

Heart Diseases (Phase 3)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis C (Phase 4)

Hepatitis C, Chronic (Phase 4)

Hepatitis, Chronic (Phase 4)

Ischemia (Phase 3)

Leukemia (Phase 3)

Mucositis (Phase 4)

Myocardial Ischemia (Phase 3)

Neuroendocrine Tumors (Phase 2)

Rectal Neoplasms (Phase 2)

Retinal Diseases (Phase 1)

Stomatitis (Phase 4)

Vitamin D Deficiency (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 40
  • # of Trial APIs: 48